Bronchial rheoplasty for chronic bronchitis: real-world evidence of safety and performance
Open Access
- 16 May 2025
- journal article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Abstract
Background: Bronchial rheoplasty (BR) addresses mucosal inflammation and hypersecretion associated with chronic bronchitis (CB) by ablating goblet cell hyperplasia with nonthermal pulsed electric fields. This study assessed if BR continues to demonstrate a safe profile and symptom burden reduction in CB patients. Methods: This observational, post-market, single-arm registry was conducted at eight centres in Austria and Germany. Patients with CB and high symptom burden (COPD assessment test (CAT) score ≥7 points in the first two questions) were treated with two bronchoscopic BR procedures. The primary outcomes were safety and symptom burden at 12 months, evaluated by (serious) adverse events ((S)AEs) and questionnaire scores (CAT and St. George's Respiratory Questionnaire (SGRQ)). Subgroup analyses were performed to identify treatment responders. Results: 106 BR procedures were performed in 54 patients (mean forced expiratory volume in 1 s (FEV 1 ) 57.8±25.3% predicted, residual volume 166.2±39.6% predicted, CAT 24.8±6.8) with a follow-up time of up to 12 months (n=40). The procedure could be performed safely, with only two SAEs (thoracic pain) and 10 respiratory AEs (mainly COPD exacerbation) deemed to be related to the device or procedure over 12 months. Patients experienced statistically significant questionnaire score improvements in CAT (−5.5±8.0 at 6 months, −4.2±7.4 at 12 months) and SGRQ at 6 and 12 months. CAT responders (improvement ≥the minimal clinically important difference of 2 points) had more preserved lung function and better exercise capacity at baseline than CAT nonresponders. Conclusion: The real-world clinical experience demonstrates that BR is a relatively safe and promising treatment option for CB patients with significant symptom burden.Keywords
Funding Information
- Galvanize Therapeutics Inc.
This publication has 19 references indexed in Scilit:
- Retreatment of symptomatic chronic bronchitis with bronchial rheoplastyBMJ Case Reports, 2024
- Bronchial rheoplasty for chronic bronchitis: 2-year results from a US feasibility study with RheOxBMJ Open Respiratory Research, 2023
- Interventional Bronchoscopic Therapies for Chronic Obstructive Pulmonary DiseaseClinics in Chest Medicine, 2020
- Follow-up outcomes of chronic obstructive pulmonary disease patients who underwent dilatation and curettage with the Karakoca resector balloonMedicine, 2018
- Safety and Histological Effect of Liquid Nitrogen Metered Spray Cryotherapy in the LungAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Use of Resector Balloon Desobstruction in Patients With Severe Chronic Obstructive Pulmonary DiseaseJournal of Bronchology & Interventional Pulmonology, 2015
- Minimum clinically important difference for the COPD Assessment Test: a prospective analysisThe Lancet Respiratory Medicine, 2014
- Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality riskThorax, 2009
- St. George's Respiratory Questionnaire: MCIDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2005
- Association of Chronic Mucus Hypersecretion With FEV1 Decline and Chronic Obstructive Pulmonary Disease Morbidity. Copenhagen City Heart Study GroupAmerican Journal of Respiratory and Critical Care Medicine, 1996